Preferred Label : Camonsertib;
NCIt synonyms : ATR Inhibitor RP-3500; 1R,3R,5S)-3-(6-((R)-3-Methylmorpholino)-1-(1H-pyrazol-3-yl)-1H-pyrazolo(3,4-b)pyridin-4-yl)-8-oxabicyclo(3.2.1)octan-3-ol; 8-Oxabicyclo(3.2.1)octan-3-ol, 3-(6-((3R)-3-methyl-4-morpholinyl)-1-(1H-pyrazol-3-yl)-1H-pyrazolo(3,4-b)pyridin-4-yl)-,
(3-endo)-;
NCIt definition : An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase,
with potential antineoplastic activity. Upon oral administration, camonsertib selectively
targets and inhibits ATR activity and blocks the downstream phosphorylation of the
serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated
signaling, which results in the inhibition of DNA damage checkpoint activation, the
disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a
serine/threonine protein kinase upregulated in a variety of cancer cell types, plays
a key role in DNA repair, cell cycle progression and survival. It is activated by
DNA damage caused during DNA replication-associated stress.;
UNII : S1Z7Y5G56T;
CAS number : 2417489-10-0;
Molecule name : RP-3500; RP 3500;
NCI Metathesaurus CUI : CL1411776;
Origin ID : C174206;
UMLS CUI : C5706579;
Semantic type(s)
- concept_is_in_subset
- has_target
